ArticlePharmaceutics2022
Preparation of PLGA-Coated Porous Silica Nanofibers for Drug Release.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Application of an innovative isoniazid-loaded biomimetic mineralized bone collagen scaffold in bone defect treatment.RSC advances · 2025Article
- Polydopamine-Coated Polymer Nanofibers for In Situ Protein Loading and Controlled Release.ACS omega · 2024Article
- Multifaceted Assessment of Porous Silica Nanocomposites: Unraveling Physical, Structural, and Biological Transformations Induced by Microwave Field Modification.Nanomaterials (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fibrous materials have unique applications in drug release and biomedical fields. This study reports on the preparation of porous silica nanofibers, using organic nanofibers as templates, and their use for drug release. Different from the commonly used electrospinning method, the organic nanofibers are produced via a self-assembly approach between melamine and benzene-1,3,5-tricarboxylic acid. Silica is then coated on the organic nanofibers via homogenization in a silica sol, a freeze-drying process, and then a sol-gel process. In order to regulate the surface area and mesopore volume of silica nanofibers, cetyltrimethyl ammonium bromide at different concentrations is used as template in the sol-gel process. With the removal of organic nanofibers and the surfactant by calcination, porous silica nanofibers are generated and then assessed as a scaffold for controlled drug release with ketoprofen as a model drug. Poly (D, L-lactide-co-glycolide) is coated on the silica nanofibers to achieve slow burst release and prolonged cumulative release of 25 days. This study demonstrates an effective method of preparing hollow silica nanofibers and the use of such nanofibers for long-term release with high drug loading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.